These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20308003)

  • 1. TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis.
    Lundberg M; Saarilahti K; Mäkitie AA; Mattila PS
    Oral Oncol; 2010 May; 46(5):369-72. PubMed ID: 20308003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor beta 1 genotype and p16 as prognostic factors in head and neck squamous cell carcinoma.
    Lundberg M; Leivo I; Saarilahti K; Mäkitie AA; Mattila PS
    Acta Otolaryngol; 2012 Sep; 132(9):1006-12. PubMed ID: 22667340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between transforming growth factor beta1 genetic polymorphism and response to chemoradiotherapy in head and neck squamous cell cancer.
    Lundberg M; Pajusto M; Koskinen WJ; Mäkitie AA; Aaltonen LM; Mattila PS
    Head Neck; 2009 May; 31(5):664-72. PubMed ID: 19260117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
    Porceddu SV; Campbell B; Rischin D; Corry J; Weih L; Guerrieri M; Grossi M; Peters LJ
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):365-73. PubMed ID: 15380568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
    Gouvêa de Lima A; Villar RC; de Castro G; Antequera R; Gil E; Rosalmeida MC; Federico MH; Snitcovsky IM
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):270-5. PubMed ID: 21163585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
    Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
    Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Su NW; Leu YS; Lee JC; Chen YJ; Chen HW; Liu CJ; Chang YF
    Acta Otolaryngol; 2011 Dec; 131(12):1333-40. PubMed ID: 22017375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
    Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG
    Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
    Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
    Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
    Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
    Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
    Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection.
    Smyth JK; Deal AM; Huang B; Weissler M; Zanation A; Shores C
    Laryngoscope; 2011 Sep; 121(9):1881-7. PubMed ID: 21997727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer.
    Wolff HA; Daldrup B; Jung K; Overbeck T; Hennies S; Matthias C; Hess CF; Roedel RM; Christiansen H
    Radiology; 2011 Mar; 258(3):864-71. PubMed ID: 21339350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.